Aspen Pharmacare has secured a landmark regulatory win after the South African Health Products Regulatory Authority (Sahpra) approved the commercial release of Aspen’s first locally manufactured human insulin batches. The products are cleared for sale in South Africa and other African markets, moving the project from planning into live supply for patients and health systems.
The insulin is produced at Aspen’s sterile finished-dose form facility in Gqeberha, Eastern Cape. The milestone marks the start of commercialisation under Aspen’s human insulin contract manufacturing agreement with Novo Nordisk, following a technical transfer process that has taken several years to deliver.
Markets reacted fast. After Aspen’s SENS update on Tuesday, 5 May 2026, the company’s share price reached a 52-week high, lifting its market capitalisation above R66 billion.
Aspen Insulin Approval Signals A Shift In Diabetes Supply Security
The timing matters. South Africa’s disease burden is changing, with non-communicable diseases rising. Aspen senior executive for strategic trade, Stavros Nicolaou, said diabetes is now “the single biggest killer in the country” among diseases. He added that diabetes has overtaken more traditional public health priorities, including HIV and tuberculosis.
For healthcare funders and providers, that trend increases pressure on reliable access to insulin. It also raises the stakes for predictable pricing and stable distribution, especially across public-sector tenders and private-sector dispensing channels.
Aspen Insulin Approval Builds On Covid-19 Lessons For Africa
Nicolaou linked the localisation drive to the continent’s experience during Covid-19, when global supply chains often favoured wealthier countries. He said African countries found themselves “at the back end of the queue”, with avoidable harm to lives and livelihoods.
Local production is being positioned as a hedge against disruption. Aspen argues that African manufacturing capacity can reduce exposure to geopolitics, logistics shocks, and shipping delays. That framing is likely to resonate with policymakers focused on resilience, industrialisation, and health security.
There is also a sustainability angle. Aspen has previously highlighted that the Gqeberha sterile manufacturing platform, which has been expanded and repurposed over time for different sterile products, can support insulin manufacturing at scale.
Pricing Pressure And Policy Interest Move Up The Agenda
Security of supply is not only about local factories. It is also about affordability and a viable manufacturing base. Nicolaou noted ongoing engagement with the health department as input costs rise, warning that sustained price pressure can threaten long-term access if the industry becomes unsustainable.
The project is also gaining political momentum beyond South Africa. Nicolaou is expected to attend the African Union–France Summit in Kenya, where pharmaceutical localisation is a priority topic. He pointed to Kenya’s President William Ruto as a leading advocate for localisation on the continent.
For the health sector, the practical question is what comes next. If volumes scale and procurement pathways are clear, locally made human insulin could strengthen continuity of care. It could also support broader industrial policy goals, from skills development to supply-chain depth.